Summary of Key Points
Connoya is an innovative pharmaceutical company listed on the Hong Kong Stock Exchange that has recently initiated a process to re-list on the STAR Market (creating an A+H dual-platform strategy). The company holds 3.24 billion yuan in cash and reported a net profit of 1.218 billion yuan in the first half of the year (mainly from a one-time gain from the sale of its overseas subsidiary; its core business has not yet turned a profit). Its key strengths include:
- Kangyueda: The company's first domestic IL-4Rα monoclonal antibody for autoimmune diseases has seen rapid sales growth (393 million yuan in the first half, exceeding the entire amount of last year), and it has been included in the national medical insurance and essential drug list. This product offers advantages in terms of fewer side effects (such as conjunctivitis) and long-term efficacy.
- CMG901: An ADC drug targeting Claudin18.2, which has received an authorization grant of 1.1 billion US dollars from AstraZeneca and shown positive results in global Phase III trials.
- NewCo Model: The company's subsidiary, Ouro, was acquired by Gilead for an upfront payment of 257 million yuan. This model has been successful, allowing Connoya to monetize its early-stage projects while not utilizing domestic R&D resources and gaining access to global markets.
Detailed Analysis
Connoya's Three Core Competencies:
Connoya's success can be attributed to three main areas:
- Kangyueda: As the first domestic IL-4Rα monoclonal antibody for autoimmune diseases, this product targets conditions such as allergies, rhinitis, and dermatitis. Instead of competing head-on with imported drugs, Connoya focused on securing an exclusive indication for "seasonal allergic rhinitis" and demonstrated advantages in side effects and long-term efficacy. Its inclusion in the medical insurance and essential drug list has enabled it to reach grassroots hospitals. A sales team of 500 people has covered over 1,500 hospitals, with sales reaching 393 million yuan in the first half of the year, indicating a period of rapid growth.
- CMG901: An ADC drug designed to precisely target cancer cells using the Claudin18.2 target. It was sold to AstraZeneca for 1.1 billion US dollars. Phase III trial results in July showed that the drug can extend the survival of gastric cancer patients, making it the first Claudin18.2 ADC to achieve this. Connoya is poised to apply for market approval, representing a successful case of a domestic innovative drug entering the global market.
- NewCo Model: This model involves splitting early-stage projects into overseas companies for joint development with foreign partners. For example, the CM336 bispecific antibody was transferred to Ouro, which was acquired by Gilead, generating an upfront payment of 257 million yuan plus ongoing royalties for Connoya. This approach not only generates revenue but also allows the company to share in the long-term benefits of the global market.
Why Return to the A-share Market?
Despite having 3.2 billion yuan in cash, Connoya is considering a re-list on the STAR Market for several reasons:
- Valuation and Liquidity: The Hong Kong stock market is dominated by foreign investors and places more emphasis on global pipelines and clinical data, often underestimating the value of domestic commercialization efforts and medical insurance benefits. As a result, companies like Connoya face lower valuations and reduced liquidity.
- A-share Market Understanding: A-share investors (including public and insurance funds) place more value on factors such as medical insurance coverage and domestic sales growth, providing better liquidity and higher valuations. The inclusion of Kangyueda in the essential drug list is seen as a significant advantage by A-share investors.
- Capital Needs for Transformation: Connoya needs capital to expand its sales network, advance new projects (such as the CM512 bispecific antibody), and pursue mergers and acquisitions. The A+H dual-platform strategy allows for flexible financing, reducing the risk associated with fluctuations in the Hong Kong market.
- Local Brand Building: Listing on the A-share market enhances the company's credibility when dealing with domestic hospitals, medical insurance authorities, and partners, and facilitates talent incentives and industry collaborations.
Challenges on the Road to Re-listing:
Re-listing on the A-share market comes with several challenges:
- Profitability Doubts: The net profit of 1.218 billion yuan in the first half mainly came from the sale of Ouro; the core business is still losing money due to high R&D and sales expenses. Regulators and investors will question the sustainability of these profits and the timing of the second commercial product.
- Red Chip Structure: As a Cayman-registered red chip company, Connoya must adjust its structure, accounting standards, and disclosure requirements, which is costly. There may also be concerns about the ownership of overseas assets, affecting the integrity of its domestic operations.
- Product Dependency: Currently, only Kangyueda is generating revenue, and with multiple domestic competitors entering the IL-4Rα market, competition will intensify, potentially leading to price wars and competition for medical resources. The success of future products is uncertain.
- Pipeline Uncertainty: The clinical outcomes of new projects, such as the CM512 bispecific antibody, are not guaranteed, and not all NewCo projects will be successfully acquired.
The Significance of Connoya's Journey:
Connoya's approach represents a significant milestone in the development of China's innovative pharmaceutical industry, transitioning from a focus on R&D to a focus on commercialization and global presence:
- Shift from Selling Pipelines to Selling Products: Many Biotechs used to sell their pipelines to larger pharmaceutical companies; Connoya has taken the steps to develop and sell its own products, completing the commercialization cycle.
- From Surface Globalization to Deep Globalization: Connoya is not merely selling overseas rights but is actively participating in the global market through the NewCo model, sharing in the long-term benefits.
- Re-listing as a Means, Not an End: The A+H dual-platform strategy helps address capital and branding issues, but whether Connoya can become a global Biopharma depends on the strength of its products. Whether Kangyueda can maintain its market position and whether CMG901 can be successfully launched is crucial.
Connoya's journey is a testament to the progress of China's innovative pharmaceutical industry, which is moving from being a follower to a leader in developing and selling effective drugs. The re-listing on the A-share market is just one step in this journey, and the real test lies in the company's ability to continuously deliver innovative products and establish a strong presence globally.
Conclusion
Connoya's story illustrates the transformation of China's innovative pharmaceutical sector from a focus on R&D to commercialization and global expansion. While there are challenges ahead, the industry has the potential for significant growth. Investors should distinguish between one-time gains and long-term business growth and approach the value of innovative drugs with a rational perspective. The road ahead is promising, though it is not without challenges. Ultimately, the focus should always be on developing drugs that can effectively treat diseases and be commercially successful.
Conclusion